OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata

- Potential first-in-disease treatment for millions of adults worldwide living with alopecia areata (AA) - - Safety data in AA showed no new safety signals for OLUMIANT up to 36 weeks of treatment in the longest Phase 3, placebo-controlled period for the JAK inhibitor class to date - - Tolerability